Table 2.
Diagnostic properties of candidate diagnostic antibodies
| Symbol | Name | Sens 90% spec | Spec | Sens | OR | p | Adj. p |
|---|---|---|---|---|---|---|---|
| cPDRG1 | p53 and DNA damage regulated 1 | 15.4 (8.7–24.9) | 42.1 | 73.5 | 7.23E+02 | 0.121 | 0.479 |
| PDGR1 | p53 and DNA damage regulated 1 | 19.8 (8.7–27.7) | 81.6 | 30.8 | 6.45E+02 | 0.099 | 0.479 |
| cFAM234A | Family with sequence similarity 234 A | 24.1 (11.1–41.1) | 82.9 | 39.9 | 1.12E+03 | 0.091 | 0.479 |
| FAM234A | Family with sequence similarity 234 A | 19.0 (11.1–33.2) | 71.1 | 51.0 | 5.12E+02 | 0.058 | 0.450 |
| cRBMS1 | RNA binding motif ss interacting prot 1 | 30 (22.9–37.6) | 94.7 | 27.7 | 2.33E+02 | 0.003 | 0.097 |
| cILKAP | ILK ass. Serine/threonine phosphatase | 25.3 (13.4–43.1) | 59.2 | 66.8 | 1.42E+02 | 0.012 | 0.250 |
| cPIN1 | Peptidylprolyl cis/trans isomerase NIMA-interacting 1 | 26.5 (15.8–38.7) | 88.2 | 32.8 | 1.96E+05 | 0.080 | 0.479 |
| cPEX14 | Peroxisomal biogenesis factor 14 | 22.1 (12.6–34.0) | 75 | 50.2 | 1.61E+04 | 0.056 | 0.450 |
| cC21orf91 | Chromosome 21 open reading frame 91 | 24.1 (17.0–35.2) | 55.3 | 61.7 | 3.52E+05 | 0.011 | 0.250 |
| cCMPK1 | Cytidine/uridine monophosphate kinase | 24.1 (18.2–31.6) | 97.4 | 20.6 | 3.88E+01 | 0.003 | 0.089 |
| cSIGIRR | Single Ig and TIR domain containing | 32.8 (23.3–44.7) | 81.6 | 44.7 | 8.85E+03 | 0.006 | 0.154 |
| cTRADD | TNFRSF1A associated via death domain | 28.5 (19.8–37.9) | 69.7 | 55.7 | 9.96E+01 | 0.002 | 0.079 |
| cHNRNPA1 | Heterogeneous nuclear ribonucleo-protein A1 | 21.7 (13.4–34.0) | 68.4 | 48.6 | 1.96E+01 | 0.034 | 0.374 |
| cPODXL2 | Podocalyxin like 2 | 28.1 (19.8–38.3) | 80.3 | 41.9 | 2.13E+02 | 0.024 | 0.363 |
| cPER1 | Period circadian regulator 1 | 24.1 (7.9–36.8) | 77.6 | 42.3 | 4.65E+01 | 0.157 | 0.479 |
| cAEBP1 | AE binding protein 1 | 21.7 (13.0–36.8) | 68.4 | 55.7 | 1.75E+02 | 0.014 | 0.270 |
| cHYOU1 | Hypoxia upregulated 1 | 23.3 (14.2–36.4) | 81.6 | 39.1 | 3.07E+03 | 0.026 | 0.366 |
| cTRA2B | Transformer 2 beta homolog | 39.1 (29.2–51.4) | 82.9 | 51 | 5.26E+03 | 0.001 | 0.047 |
| cSNRNP70 | Small nuclear ribonucleoprotein U1 subunit 70 | 28.5 (14.6–43.1) | 81.6 | 45.8 | 5.64E+02 | 0.003 | 0.099 |
| cNUMA1 | Nuclear mitotic apparatus protein 1 | 29.6 (13.0–39.1) | 89.5 | 32.4 | 9.23E+03 | 0.040 | 0.374 |
| cCRIP2 | Cysteine rich protein 2 | 28.9 (13.0–39.5) | 90.8 | 31.2 | 2.50E+02 | 0.009 | 0.204 |
| cPIP5K1C | Open reading frame | 31.2 (17.0–41.9) | 78.9 | 47 | 1.09E+04 | 0.005 | 0.120 |
| cRPRM | Reprimo. TP53 dependent G2 arrest mediator homolog | 33.6 (23.3–44.7) | 78.9 | 47.8 | 1.57E+03 | 0.004 | 0.101 |
| cVPS4A | Vacuolar protein sorting 4 homolog A | 22.9 (15.4–30.4) | 67.1 | 52.2 | 3.49E+01 | 0.020 | 0.313 |
| cNUDT16 | Nudix hydrolase 16 | 31.6 (22.9–42.3) | 86.8 | 38.3 | 9.07E+05 | 0.003 | 0.099 |
| cASMTL | Acetylserotonin O-methyltransferase like | 36.4 (26.1–44.3) | 92.1 | 35.6 | 1.63E+04 | 0.006 | 0.138 |
| cNONO | Non-POU domain containing octamer binding | 24.1 (13.8–32.0) | 51.3 | 65.2 | 5.34E+01 | 0.014 | 0.270 |
| cCASKIN1 | CASK interacting protein 1 | 20.9 (11.5–28.5) | 75 | 47.8 | 1.56E+04 | 0.037 | 0.374 |
| cSPTBN2 | Spectrin beta. Non-erythrocytic 2 | 25.7 (11.9–35.2) | 63.2 | 55.7 | 9.17E+02 | 0.029 | 0.373 |
| cKIF5B | Kinesin family member 5B | 23.7 (15.8–35.2) | 85.5 | 31.6 | 2.49E+02 | 0.017 | 0.287 |
| cGLT8D1 | Glycosyltransferase 8 domain containing 1 | 24.1 (15.0–36.8) | 81.6 | 39.9 | 9.56E+01 | 0.015 | 0.270 |
| cEIF4H | Eukaryotic translation initiation factor 4H | 28.9 (20.2–38.7) | 77.6 | 45.8 | 1.29E+03 | 0.004 | 0.099 |
| cZNF579 | Zinc finger protein 579 | 18.6 (8.7–33.2) | 81.6 | 34.4 | 2.81E+01 | 0.111 | 0.479 |
| cSNRPB | Small nuclear ribonucleoprotein polypeptides B and B1 | 17.0 (10.7–33.6) | 82.9 | 32.8 | 5.67E+02 | 0.030 | 0.373 |
Gene symbol with preceding “c” indicates antibody to citrullinated recombinant antigen. Sensitivity (Sens) at 90% specificity (Spec), otherwise at optimal area under the curve according to ROC analysis. Odds ratio (OR) for diagnosis of RA by generalized linear modeling with unadjusted p value (p), or after adjustment according to Bonferroni